Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06788535 · ClinicalTrials.gov registry record · Phase 3

Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

A Phase 3 study of Cardiac Amyloidosis, sponsored by Sharmila Dorbala.

Active
Registry status
Phase 3
Development phase
200
Enrollment target
20
Study locations

NCT06788535: Active Phase 3 study of Cardiac Amyloidosis, sponsored by Sharmila Dorbala.

NCT06788535 is a Phase 3 study of Cardiac Amyloidosis that is active but no longer recruiting, run by Sharmila Dorbala. The registered enrollment target is 200 participants, below the 930-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06788535, a Phase 3 study of Cardiac Amyloidosis, is active but no longer recruiting, sponsored by Sharmila Dorbala.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.

Primary Outcome

Assessment of the sensitivity of PET/CT imaging with I-124 evuzamitide for the diagnosis of cardiac amyloidosis based on visual scan interpretation.

Conditions Studied

Interventions

  • DRUG I-124 evuzamitide

Study Locations (20)

California

  • City of Hope - Duarte - Duarte
  • University of California - San Francisco

Illinois

  • Northwestern University - Chicago
  • Cook County Health - Chicago

Missouri

  • St. Lukes (CVIT) Saint Luke's Health System - Kansas City
  • Washington University of St. Louis - St Louis

North Carolina

  • Duke University - Durham
  • Cone Health - Greensboro

Arizona

  • Mayo Clinic - Scottsdale

Connecticut

  • Yale Cardiovascular Medicine - New Haven

Florida

  • Cleveland Clinic - Weston

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-01-14
Est. Completion 2026-02-13
Phase Phase 3
Sharmila Dorbala

1 total trials

What the registry record for NCT06788535 still lists

NCT06788535 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 930-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which I-124 evuzamitide is the first listed.

NCT06788535 names 20 study sites across 16 states, led by California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT06788535 about?

NCT06788535 is a clinical study titled "Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis". The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emiss...

What is the current status of trial NCT06788535?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-01-14. Estimated completion is 2026-02-13.

What conditions does trial NCT06788535 study?

This clinical trial studies the following conditions: Cardiac Amyloidosis.

What interventions are being tested in trial NCT06788535?

The interventions under investigation include: I-124 evuzamitide (DRUG).

Who is sponsoring clinical trial NCT06788535?

This trial is sponsored by Sharmila Dorbala, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06788535 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06788535's enrollment target sits among peer trials

200 4th of 8 higher than 4 of 8 other Cardiac Amyloidosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiac Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06788535, the US trial registry maintained by the National Library of Medicine. NCT06788535 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.